Yeast studies provide clue about controlling cholesterol levelsDecember 3rd, 2008 - 6:48 pm ICT by ANI
Washington, December 3 (ANI): Johns Hopkins researchers say that they have gained significant insights into the mechanism whereby a single-celled fungus regulates its version of cholesterol.
Writing about their work in the journal Cell Metabolism, the researchers say that their work may help better understand the target and action of cholesterol-lowering drugs taken daily by millions of people to stave off heart attacks and strokes.
Statin drugs inhibit an enzyme, HMG-CoA reductase, to lower blood cholesterol.
The researhcers say that a yeast called fission yeast, so named because they divide in the middle, is a good model for delving fast and deep into molecular details of how mammalian cells regulate HMG-CoA reductase.
They have thus far found that in these yeast, the regulatory protein Insig also regulates HMG-CoA reductase but does it differently.
According to them, Insig degrades this enzyme in mammalsessentially destroying itwhile in fission yeast, Insig inactivates the enzyme simply by promoting the attachment of a phosphate.
“This is a surprising fundamental difference,” says Peter J. Espenshade, a physiologist in the Department of Cell Biology and member of the Center for Metabolism and Obesity Research at the Johns Hopkins University School of Medicine.
He revealed that studies on fission yeast have so far shown that the protein Insig happily go about their business of manufacturing cholesterol in just the right amounts when all is well with cells.
As in humans, Insig in yeast limits cholesterol production by inactivating the enzyme HMG-CoA reductase.
However, how the yeast stopped synthesizing cholesterol was what surprised the scientists.
According to them, stressed fission yeast activated a protein called MAPK which, partnering with the protein Insig, attaches a phosphate onto the enzyme HMG-CoA reductase by a process known as phosphorylation and shuts down cholesterol manufacture.
The researchers say that their findings shed light on how a cell can change cholesterol production in response to a stressful environment.
“In this study, we not only learned something new about how Insig works and cholesterol biology, but we also found a rare example of a MAPK controlling a biosynthetic enzyme,” Espenshade says.
By studying Insig control of HMG-CoA reductase in yeast, the researchers hope to inform improvements to the efficacy of statin and other cholesterol-lowering therapies. (ANI)
- Promising new way to lower cholesterol production - Mar 03, 2011
- Statins may be effective against cancer - Oct 28, 2009
- Birch bark ingredient has an array of metabolic benefits - Jan 05, 2011
- Discovery shows statins could fight cancer - Sep 14, 2012
- Why statins work for some people, but not for all - Apr 22, 2010
- Cholesterol-lowering statins 'kill bacteria' - Nov 18, 2010
- Long-term statin 'unlikely to increase cancer risk' - Nov 10, 2010
- Statin can prevent strokes, besides lowering lipids - Jan 05, 2012
- 'Good' cholesterol drug may help diabetics - Jul 19, 2011
- Cholesterol drugs may be effective against cancer too - Oct 28, 2009
- Cholesterol busting drugs might be bad for you - Dec 21, 2010
- Anti cholesterol drug causes depression: Indian scientists - Jun 23, 2010
- Study sheds light on RNA 'on/off switches' - Feb 14, 2011
- Fewer calories spell longer life, protection from diabetes - Nov 01, 2011
- Statins stave off depression in heart patients - Feb 26, 2012
Tags: blood cholesterol, cell biology, cell metabolism, cholesterol levels, cholesterol lowering drugs, cholesterol production, espenshade, fission yeast, fundamental difference, hopkins researchers, insig, johns hopkins university, johns hopkins university school, johns hopkins university school of medicine, mammalian cells, molecular details, obesity research, regulatory protein, statin drugs, target